Mersana Therapeutics, Inc. (MRSN) Dividend History

Company News

• Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

  Mersana Therapeutics announced a strategic restructuring and reprioritization plan to focus on advancing its Emi-Le drug candidate for triple-negative breast cancer. The company reported updated clinical data for Emi-Le and plans to report initial expansion data in the second half of 2025.

  GlobeNewswire Inc.
• Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

  Mersana Therapeutics announced a strategic restructuring plan to focus on the development of its lead drug candidate Emi-Le for triple-negative breast cancer. The plan includes a 55% workforce reduction and deprioritization of other pipeline programs to extend the company's cash runway.

  GlobeNewswire Inc.
• Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

  Mersana Therapeutics announced that Phase 1 clinical data for its antibody-drug conjugate Emi-Le will be presented at the ESMO Breast Cancer 2025 Annual Congress. Emi-Le is being investigated for the treatment of solid tumors, including breast, endometrial, and ovarian cancers.

  GlobeNewswire Inc.
• Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

  Mersana Therapeutics reported positive initial Phase 1 data for its lead ADC candidate Emi-Le, which is being developed for triple-negative breast cancer. The company also announced the initiation of an expansion cohort and a Fast Track designation from the FDA. Mersana continues to advance the dose escalation portion of its Phase 1 trial for XMT-2056, its lead Immunosynthen ADC candidate.

  GlobeNewswire Inc.
• Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

  Mersana Therapeutics provided updates on the progress of its clinical trials for XMT-1660 and XMT-2056, as well as its collaborations with Johnson & Johnson and Merck KGaA. The company reported financial results for the third quarter of 2024, including a net loss of $11.5 million.

  GlobeNewswire Inc.

  Featured Companies: JNJ